Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Stock Has Consensus Target Price of $3.17

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been assigned a consensus rating of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $4.00.

A number of research analysts have recently weighed in on INO shares. HC Wainwright set a $5.00 price objective on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Monday. Weiss Ratings cut shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 13th. Jefferies Financial Group raised shares of Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and increased their target price for the stock from $1.80 to $3.00 in a research report on Thursday, August 13th. Piper Sandler restated an “overweight” rating and set a $4.00 target price on shares of Inovio Pharmaceuticals in a report on Monday, August 3rd. Finally, Zacks Research cut Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 12th.

Key Inovio Pharmaceuticals News

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: FDA accelerated approval of VOCERYQ provides Inovio with its first approved product and could support future sales, commercialization partnerships, and broader investor confidence in its DNA medicines. INOVIO Receives FDA Accelerated Approval for VOCERYQ
• Positive Sentiment: HC Wainwright upgraded Inovio from “neutral” to “buy” following the FDA decision, adding sell-side support to the rally. Inovio Shares Surge After HC Wainwright Upgrade
• Positive Sentiment: Management will present data on its DNA medicine programs, including INO-D001 for hemophilia A, at upcoming scientific conferences, potentially increasing visibility for its pipeline. INOVIO to Participate in Upcoming Scientific Conferences

Inovio Pharmaceuticals Stock Performance

NASDAQ:INO opened at $1.89 on Tuesday. The stock’s 50 day moving average price is $1.15 and its 200 day moving average price is $1.27. Inovio Pharmaceuticals has a 52 week low of $0.56 and a 52 week high of $2.72. The company has a market capitalization of $195.43 million, a P/E ratio of -2.08 and a beta of 1.61.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15. As a group, sell-side analysts forecast that Inovio Pharmaceuticals will post -0.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in INO. Headlands Technologies LLC bought a new stake in Inovio Pharmaceuticals during the second quarter worth approximately $33,000. Engineers Gate Manager LP acquired a new position in Inovio Pharmaceuticals during the second quarter valued at approximately $37,000. Squarepoint Ops LLC raised its position in shares of Inovio Pharmaceuticals by 46.5% in the second quarter. Squarepoint Ops LLC now owns 36,391 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 11,554 shares during the period. Prime Capital Investment Advisors LLC raised its position in shares of Inovio Pharmaceuticals by 312.4% in the third quarter. Prime Capital Investment Advisors LLC now owns 70,636 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 53,510 shares during the period. Finally, LexAurum Advisors LLC bought a new position in shares of Inovio Pharmaceuticals in the third quarter valued at approximately $118,000. 26.79% of the stock is owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells.

Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.